IN THE SPECIFICATION:

Please amend the specification as follows.

In compliance with 37 C.F.R. § 1.823(a), please insert the attached paper copy of the "Sequence Listing" after the last page of the above-identified application.

Paragraph 9, pages 2 and 3.

The present invention provides compositions comprising a peptide having the formula R'-Glx-Glx-Lys-R" or a pharmaceutically acceptable salt thereof; wherein Glx is Glu or Gln; R' is H- or a first amino acid sequence having fewer than 7 amino acids; R" is –H or a second amino acid sequence having fewer than 7 amino acids; and the peptide has a sequence of at least 5 and not more than 9 amino acids. Generally, R' is H-, Thr-Ala-, Thr-Pro, Ser-Ala-, Ser-Pro-, Ser-Ser, Met-Leu-Thr-Ala- (SEQ. ID NO.: 1), or Leu-Thr-Ala; and R" is –H, -Ala, -Ala-Ala or-Ala-Val. In preferred embodiments, the peptide is L-Thr-L-Pro-L-Glu-L-Glu-L-Lys (SEQ. ID NO.: 2), or L-Thr-L-Ala-L-Glu-L-Glu-L-Lys (SEQ. ID NO.: 3)

Paragraph 10, page 3.

Also provided are pharmaceutical preparations comprising a peptide having the formula R'-Glx-Lys-R" or a pharmaceutically acceptable salt thereof, wherein Glx is Glu or Gln; R' is H- or a first amino acid sequence having fewer than 7 amino acids, R" is –H or a second amino acid sequence having fewer than 7 amino acids; and the peptide has a sequence of at least 2 and not more than 9 amino acids; and a physiologically acceptable carrier. In preferred embodiments, the peptide is L-Glu-L-Lys, L-Thr-L-Ala-L-Glu-L-Glu-L-Lys (SEQ. ID NO.:3) or L-Thr-L-Pro-L-Glu-L-Glu-L-Lys (SEQ. ID NO.: 2).

Paragraph 29, page 5.

R' is H-, Thr-Ala-Glx-, Thr-Pro-Glx-, Ser-Ala-Glx-, Ser-Pro-Glx, Ser-Ser-Glx, Met-Leu-Thr-Ala-Glx- (SEQ. ID. NO.: 4), or Leu-Thr-Ala-Glx- (SEQ. ID NO.: 5);

Paragraph 36, page 5.

Preferred species are Glx-Lys and Thr-Ala-Glx-Glx-Lys (SEQ. ID NO.: 6), particularly wherein Glx=Glu. The amino acids of the peptides of the present invention may be either D or L stereoisomers. The amino acids in a peptide may all be either L or D or a mixture of L and D stereoisomers. It is generally preferred that all of the amino acids be of the L form. Specific amino acid stereoisomers will be denoted by a prefix of L- or D-. For example, the L stereoisomer of alanine is denoted L-Ala.

Paragraph 41, page 6.

R' = Met-Leu-Thr-Ala-Glx- (SEQ. ID NO.:4) and R"=-Ala;

Paragraph 42, page 6.

R' = Leu-Thr-Ala-Glx- (SEQ. ID NO.: 5) and R"=-Ala;

Paragraph 43, page 6.

R' = Leu-Thr-Ala-Glx- (SEQ. ID NO.: 5) and R"=-Ala-Ala;

Paragraph 44, page 6.

R' = Leu=Thr-Ala-Glx- (SEQ. ID NO.: 5) and R"=-Ala-Val

Paragraph 58, pages 9 and 10.

The present invention provides methods of using the compositions and preparations of the present invention. The methods generally comprise administering to the host a peptide having the formula R'-Glx-Lys-R" or a pharmaceutically acceptable salt thereof, wherein Glx is Glu or Gln; R' is H- or a first amino acid sequence having fewer than 7 amino acids; R" is –H or a second amino acid sequence having fewer than 7 amino acids; and the peptide has a sequence of at least 2 and not more than 9 amino acids. A therapeutic or prophylactic amount of the peptide will typically be administered. Generally either Glx-Lys and Thr-Ala-Glx-Glx-Lys (SEQ. ID NO.: 6) will be employed in the claimed methods although other peptides may be used.

Paragraph 109, page 19.

This example demonstrates the efficacy of pharmaceutical preparations containing the peptide Thr-Ala-Glu-Glu-Lys (SEQ. ID NO.:3) (HN897) for the treatment of infection. Mice inoculated with lethal doses of methicillin-resistant *Staphylococcus aureus* were shown to have markedly enhanced survival when treated with the pharmaceutical preparation, although HM897 alone appears to have no measurable specific antibiotic activity (MIC values>1000) in petri culture experiments.

Paragraph 116, page 23.

This example demonstrates the augmentation of a vaccine by administration of a peptide Thr-Ala-Glu-Glu-Lys (SEQ. ID NO.: 3) (HM897). Administration of HM897 following vaccination provided enhanced protection against infection.